drugset / Trial / NCT06397235
DEB-TACE+RALOX-HAIC vs DEB-TACE for Large HCC
Phase 2
Recruiting
130 enrolled
Second Affiliated Hospital of Guangzhou Medical University
Guangzhou Development District Hospital · collabThe Affiliated Shunde Hospital of Jinan University · collabZhongshan People's Hospital, Guangdong, China · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is conducted to evaluate the efficacy and safety of transarterial chemoembolization with drug-eluting beads (DEB-TACE) combined with hepatic artery infusion chemotherapy (HAIC) with oxaliplatin and raltitrexed (RALOX-HAIC) versus DEB-TACE alone for unresectable large hepatocellular carcinoma (HCC).
Timeline
- Start
- 2024-05-01
- Primary completion
- 2027-04-30
- Completion
- 2028-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Oxaliplatin | Small molecule | 85 mg/m2 | Other |
| Subject | Raltitrexed | Small molecule | 3 mg/m2 | Other |
| Background | Pirarubicin | Small molecule | 60 mg | Other |